

Effects of early versus delayed initiation of antiretroviral
of HIV-1 infection: results from the phase 3 HPTN 052 ra

Lancet Infectious Diseases, The
14, 281-290

DOI: 10.1016/s1473-3099(13)70692-3

Citation Report

#	ARTICLE	IF	CITATIONS
1	High Levels of Heterogeneity in the HIV Cascade of Care across Different Population Subgroups in British Columbia, Canada. PLoS ONE, 2014, 9, e115277.	2.5	62
2	Realizing the Potential of Treatment as Prevention: Global ART Policy and Treatment Coverage. Current HIV/AIDS Reports, 2014, 11, 479-486.	3.1	16
3	Rapid plasma viral suppression in naive HIV-infected patients with high CD4 cells and low viraemia initiating a dual nucleoside reverse transcriptase inhibitor strategy: a proof-of-concept study. Journal of Antimicrobial Chemotherapy, 2014, 69, 3356-3359.	3.0	2
4	The economics, financing and implementation of HIV treatment as prevention: What will it take to get there?. African Journal of AIDS Research, 2014, 13, 109-119.	0.9	13
5	Review of policy and status of implementation of collaborative HIV-TB activities in 23 high-burden countries. International Journal of Tuberculosis and Lung Disease, 2014, 18, 1149-1158.	1.2	38
6	Palliative HIV Care: Opportunities for Biomedical and Behavioral Change. Current HIV/AIDS Reports, 2014, 11, 404-412.	3.1	6
7	Successful antiretroviral therapy delivery and retention in care among asymptomatic individuals with high CD4+ T-cell counts above 350 cells/ μ l in rural Uganda. Aids, 2014, 28, 2241-2249.	2.2	28
8	HIV. Current Opinion in Infectious Diseases, 2014, 27, 545-553.	3.1	17
9	HIV Prevention in Clinical Care Settings. JAMA - Journal of the American Medical Association, 2014, 312, 390.	7.4	109
10	Balancing the need to rapidly scale-up and improve clinical outcomes in antiretroviral programmes in developing countries: lessons from an Indian programmatic cohort study. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2014, 108, 599-600.	1.8	1
11	Targeting HIV latency: resting memory T cells, hematopoietic progenitor cells and future directions. Expert Review of Anti-Infective Therapy, 2014, 12, 1187-1201.	4.4	18
12	Antiretroviral treatment initiation. Lancet Infectious Diseases, The, 2014, 14, 1175.	9.1	0
13	Antiretroviral treatment initiation. Lancet Infectious Diseases, The, 2014, 14, 1175-1176.	9.1	1
14	Antiretroviral treatment initiation – Authors' reply. Lancet Infectious Diseases, The, 2014, 14, 1176-1177.	9.1	0
15	A scoping study to identify opportunities to advance the ethical implementation and scale-up of HIV treatment as prevention: priorities for empirical research. BMC Medical Ethics, 2014, 15, 54.	2.4	12
16	Antiretroviral Therapy. Infectious Disease Clinics of North America, 2014, 28, 403-420.	5.1	7
17	HIV Treatment. Current Treatment Options in Infectious Diseases, 2014, 6, 271-293.	1.9	0
18	End of the debate about antiretroviral treatment initiation. Lancet Infectious Diseases, The, 2014, 14, 258-259.	9.1	12

#	ARTICLE	IF	CITATIONS
19	Trends in AIDS-Defining Opportunistic Illnesses Incidence over 25 Years in Rio de Janeiro, Brazil. PLoS ONE, 2014, 9, e98666.	2.5	36
20	Adherence to Early Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, 234-240.	2.1	57
21	Challenges, successes and patterns of enrolment in the INSIGHT S strategic Timing of AntiRetroviral Treatment (START) trial. HIV Medicine, 2015, 16, 14-23.	2.2	7
22	HIV infection. Nature Reviews Disease Primers, 2015, 1, 15035.	30.5	340
23	A Microperfusion and In-Bore Oxygenator System Designed for Magnetic Resonance Microscopy Studies on Living Tissue Explants. Scientific Reports, 2015, 5, 18095.	3.3	7
24	IAPAC Guidelines for Optimizing the HIV Care Continuum for Adults and Adolescents. Journal of the International Association of Providers of AIDS Care, 2015, 14, S3-S34.	1.5	95
25	Change of treatment guidelines and evolution of ART initiation in rural South Africa: data of a large HIV care and treatment programme. BMC Infectious Diseases, 2015, 15, 452.	2.9	19
26	Predictors of antiretroviral therapy initiation: a cross-sectional study among Chinese HIV-infected men who have sex with men. BMC Infectious Diseases, 2015, 15, 570.	2.9	20
27	Australian health care providers'™ views on opt-out HIV testing. BMC Public Health, 2015, 15, 888.	2.9	4
28	Quality of life in persons living with HIV in Burkina Faso: a follow-up over 12 months. BMC Public Health, 2015, 15, 1119.	2.9	14
29	Fertility Decision-Making Among Kenyan HIV-Serodiscordant Couples Who Recently Conceived: Implications for Safer Conception Planning. AIDS Patient Care and STDs, 2015, 29, 510-516.	2.5	29
30	An update on the HIV treatment cascade in children and adolescents. Current Opinion in HIV and AIDS, 2015, 10, 411-419.	3.8	19
31	Characteristics of HIV patients who missed their scheduled appointments. Revista De Saude Publica, 2015, 49, .	1.7	3
32	Challenges and Opportunities for T-Cell-Mediated Strategies to Eliminate HIV Reservoirs. Frontiers in Immunology, 2015, 6, 506.	4.8	23
33	Risk of Active Tuberculosis in HIV-Infected Patients in Taiwan with Free Access to HIV Care and a Positive T-Spot.TB Test. PLoS ONE, 2015, 10, e0125260.	2.5	6
34	A Successful Failure: Missing the MDG4 Target for Under-Five Mortality in South Africa. PLoS Medicine, 2015, 12, e1001926.	8.4	6
35	Trends in AIDS Deaths, New Infections and ART Coverage in the Top 30 Countries with the Highest AIDS Mortality Burden; 1990-2013. PLoS ONE, 2015, 10, e0131353.	2.5	121
36	Knowledge, Beliefs and Practices Regarding Antiretroviral Medications for HIV Prevention: Results from a Survey of Healthcare Providers in New England. PLoS ONE, 2015, 10, e0132398.	2.5	90

#	ARTICLE	IF	CITATIONS
37	Estimated Costs for Delivery of HIV Antiretroviral Therapy to Individuals with CD4+ T-Cell Counts >350 cells/uL in Rural Uganda. PLoS ONE, 2015, 10, e0143433.	2.5	15
39	Strategies to prevent HIV transmission to serodiscordant couples. Revista Brasileira De Epidemiologia, 2015, 18, 169-182.	0.8	7
40	The 2015 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected Koreans. Infection and Chemotherapy, 2015, 47, 205.	2.3	10
41	Mycobacterium tuberculosis: 2014 Clinical Trials in Review. Canadian Journal of Infectious Diseases and Medical Microbiology, 2015, 26, 11-14.	1.9	2
42	Estimation of the HIV Incidence and of the Number of People Living With HIV/AIDS in Brazil, 2012. Journal of AIDS & Clinical Research, 2015, 06, .	0.5	17
43	Impact of antiretroviral therapy (ART) timing on chronic immune activation/inflammation and end-organ damage. Current Opinion in HIV and AIDS, 2015, 10, 35-42.	3.8	60
44	Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand. AIDS Research and Therapy, 2015, 12, 12.	1.7	82
45	Influence of the Timing of Antiretroviral Therapy on the Potential for Normalization of Immune Status in Human Immunodeficiency Virus 1 "Infected Individuals. JAMA Internal Medicine, 2015, 175, 88.	5.1	69
46	Why <sc>START</sc>? Reflections that led to the conduct of this large long-term strategic <sc>HIV</sc> trial. HIV Medicine, 2015, 16, 1-9.	2.2	26
47	Medication-Taking Practices of Patients on Antiretroviral HIV Therapy: Control, Power, and Intentionality. AIDS Patient Care and STDs, 2015, 29, 606-616.	2.5	16
48	Health-care providers' experiences with opt-out HIV testing: a systematic review. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2015, 27, 1455-1467.	1.2	15
49	Preventing the transmission of American trypanosomiasis and its spread into non-endemic countries. Infectious Diseases of Poverty, 2015, 4, 60.	3.7	54
50	Life expectancy among HIV-positive patients in Rwanda: a retrospective observational cohort study. The Lancet Global Health, 2015, 3, e169-e177.	6.3	96
51	Reassessment of HIV-1 Acute Phase Infectivity: Accounting for Heterogeneity and Study Design with Simulated Cohorts. PLoS Medicine, 2015, 12, e1001801.	8.4	75
52	Targeting HIV Prevention Based on Molecular Epidemiology Among Deeply Sampled Subnetworks of Men Who Have Sex With Men. Clinical Infectious Diseases, 2015, 61, 1462-1468.	5.8	53
53	Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. Lancet HIV, the, 2015, 2, e335-e343.	4.7	52
54	Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. New England Journal of Medicine, 2015, 373, 795-807.	27.0	2,232
55	A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. New England Journal of Medicine, 2015, 373, 808-822.	27.0	1,028

#	ARTICLE	IF	CITATIONS
56	AIDS incidence and AIDS-related mortality in British Columbia, Canada, between 1981 and 2013: a retrospective study. <i>Lancet HIV</i> , 2015, 2, e92-e97.	4.7	54
57	Patient Loss to Follow-Up Before Antiretroviral Therapy Initiation in Rural Mozambique. <i>AIDS and Behavior</i> , 2015, 19, 666-678.	2.7	25
58	Addressing social issues in a universal HIV test and treat intervention trial (ANRS 12249 TasP) in South Africa: methods for appraisal. <i>BMC Public Health</i> , 2015, 15, 209.	2.9	32
59	Tuberculosis incidence after 36 months of isoniazid prophylaxis in HIV-infected adults in Botswana. <i>Aids</i> , 2015, 29, 351-359.	2.2	44
60	Population-Based Surveillance of HIV Drug Resistance Emerging on Treatment and Associated Factors at Sentinel Antiretroviral Therapy Sites in Namibia. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, 463-471.	2.1	14
61	Overcoming the challenge of diagnosis of early HIV infection: a stepping stone to optimal patient management. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 1189-1193.	4.4	6
62	Benefits of combined preventive therapy with co-trimoxazole and isoniazid in adults living with HIV: time to consider a fixed-dose, single tablet coformulation. <i>Lancet Infectious Diseases</i> , 2015, 15, 1492-1496.	9.1	21
63	The prevalence and determinants of drug-resistance-associated mutations in the HIV-1-infected MSM population of Henan Province in China. <i>Archives of Virology</i> , 2015, 160, 2051-2061.	2.1	10
64	HIV Epidemic in Asia: Implications for HIV Vaccine and Other Prevention Trials. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 1060-1076.	1.1	29
65	Demographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. <i>HIV Medicine</i> , 2015, 16, 30-36.	2.2	8
66	HIV Care Continuum Among Men Who Have Sex With Men and Persons Who Inject Drugs in India: Barriers to Successful Engagement. <i>Clinical Infectious Diseases</i> , 2015, 61, civ669.	5.8	57
67	Exploring the Relationship between Adherence to Treatment and Viral Load through a New Discrete Simulation Model of HIV Infectivity. , 2015, , .		11
68	Editorial Commentary: Scaling Up Antiretroviral Preexposure Prophylaxis: Moving From Trials to Implementation. <i>Clinical Infectious Diseases</i> , 2015, 61, 1598-1600.	5.8	21
69	Effect of baseline CD4 cell count at linkage to HIV care and at initiation of antiretroviral therapy on mortality in HIV-positive adult patients in Rwanda: a nationwide cohort study. <i>Lancet HIV</i> , 2015, 2, e376-e384.	4.7	14
70	Virologic suppression among HIV-infected US Air Force members in a highly-structured programme with free access to care. <i>International Journal of STD and AIDS</i> , 2015, 26, 951-959.	1.1	6
71	Factors associated with HIV viral load suppression on antiretroviral therapy in Vietnam. <i>Journal of Virus Eradication</i> , 2016, 2, 94-101.	0.5	57
72	TB as a cause of hospitalization and in-hospital mortality among people living with HIV worldwide: a systematic review and meta-analysis. <i>Journal of the International AIDS Society</i> , 2016, 19, 20714.	3.0	108
73	Use of peers to improve adherence to antiretroviral therapy: a global network meta-analysis. <i>Journal of the International AIDS Society</i> , 2016, 19, 21141.	3.0	28

#	ARTICLE	IF	CITATIONS
74	Gaps in the Continuum of HIV Care: Long Pretreatment Waiting Time between HIV Diagnosis and Antiretroviral Therapy Initiation Leads to Poor Treatment Adherence and Outcomes. <i>BioMed Research International</i> , 2016, 2016, 1-8.	1.9	11
75	New Biomedical Technologies and Strategies for Prevention of HIV and Other Sexually Transmitted Infections. <i>Journal of Sexually Transmitted Diseases</i> , 2016, 2016, 1-10.	1.0	1
76	CD4 Variability in Malawi: Implications for Use of a CD4 Threshold of 500 Cells/mm ³ Versus Universal Eligibility for Antiretroviral Therapy. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw180.	0.9	2
77	The Men Who Have Sex with Men HIV Care Cascade in Rio de Janeiro, Brazil. <i>PLoS ONE</i> , 2016, 11, e0157309.	2.5	16
78	Increased antiretroviral therapy prescription and HIV viral suppression among persons receiving clinical care for HIV infection. <i>Aids</i> , 2016, 30, 2117-2124.	2.2	46
79	Timing of Antiretroviral Treatment, Immunovirologic Status, and TB Risk: Implications for Testing and Treatment. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, 572-578.	2.1	6
80	Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 191.	7.4	533
81	“Making it personal” ideology, the arts, and shifting registers in health promotion. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2016, 28, 72-82.	1.2	6
82	Scale-up of ART in Malawi has reduced case notification rates in HIV-positive and HIV-negative tuberculosis. <i>Public Health Action</i> , 2016, 6, 247-251.	1.2	11
83	HIV care and treatment experiences among female sex workers living with HIV in sub-Saharan Africa: A systematic review. <i>African Journal of AIDS Research</i> , 2016, 15, 377-386.	0.9	90
84	HIV Self-Testing: a Review of Current Implementation and Fidelity. <i>Current HIV/AIDS Reports</i> , 2016, 13, 107-115.	3.1	87
85	Evaluation of SMARTube to Detect HIV Infection Before Seroconversion Using Standard Methods. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 1067-1071.	1.1	1
86	Methadone maintenance therapy and viral suppression among HIV-infected opioid users: The impacts of crack and injection cocaine use. <i>Drug and Alcohol Dependence</i> , 2016, 168, 211-218.	3.2	17
87	Morbidity and nutrition status of rural drug-naïve Kenyan women living with HIV. <i>African Journal of AIDS Research</i> , 2016, 15, 283-291.	0.9	0
88	Antiretroviral treatment regardless of CD4 count: the universal answer to a contextual question. <i>AIDS Research and Therapy</i> , 2016, 13, 27.	1.7	62
89	What Community-Based HIV Prevention Organizations Say About Their Role in Biomedical HIV Prevention. <i>AIDS Education and Prevention</i> , 2016, 28, 426-439.	1.1	14
90	Reply to Cohen et al. <i>Clinical Infectious Diseases</i> , 2016, 63, 1680-1680.	5.8	1
91	Promoting uptake of child HIV testing: an evaluation of the role of a home visiting program for orphans and vulnerable children in South Africa. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2016, 28, 7-13.	1.2	20

#	ARTICLE	IF	CITATIONS
92	HIV-1-RNA in seminal plasma correlates with detection of HIV-1-DNA in semen cells, but not with CMV shedding, among MSM on successful antiretroviral regimens: Table 1. Journal of Antimicrobial Chemotherapy, 2016, 71, 3202-3205.	3.0	17
93	Prevention strategies for blood-borne viruses in the Era of vaccines, direct acting antivirals and antiretroviral therapy. Reviews in Medical Virology, 2016, 26, 330-339.	8.3	17
94	Antiretroviral Therapy for the Prevention of HIV-1 Transmission. New England Journal of Medicine, 2016, 375, 830-839.	27.0	1,282
95	Improved Survival in HIV Treatment Programmes in Asia. Antiviral Therapy, 2016, 21, 517-527.	1.0	18
96	Challenges in initiating antiretroviral therapy for all HIV-infected people regardless of CD4 cell count. Infectious Diseases of Poverty, 2016, 5, 85.	3.7	46
97	Lessons from HIV-1 vaccine efficacy trials. Current Opinion in HIV and AIDS, 2016, 11, 607-613.	3.8	21
98	Antiretroviral medication treatment for all HIV-infected individuals: a protocol using innovative multilevel methodologies to evaluate New York City's universal ART policy among problem substance users. BMC Health Services Research, 2016, 16, 341.	2.2	5
99	How have guidelines on when to start antiretroviral therapy affected survival of people living with HIV infection?. Current Opinion in HIV and AIDS, 2016, 11, 487-491.	3.8	14
100	Determinants of time to antiretroviral treatment initiation and subsequent mortality on treatment in a cohort in rural northern Malawi. AIDS Research and Therapy, 2016, 13, 24.	1.7	7
101	New York City Achieves the UNAIDS 90-90-90 Targets for HIV-Infected Whites but Not Latinos/Hispanics and Blacks. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, e59-e62.	2.1	27
102	Conditional Cash Transfers to Increase Retention in PMTCT Care, Antiretroviral Adherence, and Postpartum Virological Suppression: A Randomized Controlled Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, S124-S129.	2.1	43
103	HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4+ T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial. Retrovirology, 2016, 13, 34.	2.0	33
104	Long-Acting Injectable Preexposure Prophylaxis for HIV Prevention in South Africa: Is There a Will and a Way?. Journal of Infectious Diseases, 2016, 213, 1519-1520.	4.0	7
105	Immune recovery in HIV-infected patients after Candida esophagitis is impaired despite long-term antiretroviral therapy. Aids, 2016, 30, 1923-1933.	2.2	6
106	CD4 cell count at initiation of ART, long-term likelihood of achieving CD4 >750 cells/mm ³ and mortality risk. Journal of Antimicrobial Chemotherapy, 2016, 71, 2654-2662.	3.0	27
107	Antiretroviral Therapy to Prevent HIV Acquisition in Serodiscordant Couples in a Hyperendemic Community in Rural South Africa. Clinical Infectious Diseases, 2016, 63, 548-554.	5.8	30
108	Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results From the HIV Prevention Trials Network 052 Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 304-309.	2.1	14
109	The role of antiretroviral therapy in reducing TB incidence and mortality in high HIV-TB burden countries. Asian Pacific Journal of Tropical Disease, 2016, 6, 243-247.	0.5	1

#	ARTICLE	IF	CITATIONS
110	Pattern, Determinants, and Impact of HIV Spending on Care and Treatment in 38 High-Burden Low- and Middle-Income Countries. <i>Journal of the International Association of Providers of AIDS Care</i> , 2016, 15, 91-100.	1.5	24
111	Predictors of opportunistic illnesses incidence in post combination antiretroviral therapy era in an urban cohort from Rio de Janeiro, Brazil. <i>BMC Infectious Diseases</i> , 2016, 16, 134.	2.9	12
112	Implementation challenges and opportunities for HIV Treatment as Prevention (TasP) among young men in Vancouver, Canada: a qualitative study. <i>BMC Public Health</i> , 2016, 16, 262.	2.9	18
113	The good, the bad and the ugly: determinants of antiretroviral-associated toxicities. <i>Future Virology</i> , 2016, 11, 239-243.	1.8	0
114	The rise and fall of tuberculosis in Malawi: associations with HIV infection and antiretroviral therapy. <i>Tropical Medicine and International Health</i> , 2016, 21, 101-107.	2.3	27
115	CD4 Cell Count: Declining Value for Antiretroviral Therapy Eligibility. <i>Clinical Infectious Diseases</i> , 2016, 62, 1022-1028.	5.8	21
116	Integrated prevention of mother-to-child HIV transmission services, antiretroviral therapy initiation, and maternal and infant retention in care in rural north-central Nigeria: a cluster-randomised controlled trial. <i>Lancet HIV</i> , 2016, 3, e202-e211.	4.7	71
117	Retention in Early Care at an HIV Outpatient Clinic in Rio de Janeiro, Brazil, 2000-2013. <i>AIDS and Behavior</i> , 2016, 20, 1039-1048.	2.7	10
118	Optimization of Multicomponent Behavioral and Biobehavioral Interventions for the Prevention and Treatment of HIV/AIDS. <i>AIDS and Behavior</i> , 2016, 20, 197-214.	2.7	125
119	Getting the balance right: Scaling-up treatment and prevention. <i>Global Public Health</i> , 2017, 12, 483-497.	2.0	4
120	HIV-infected presumptive tuberculosis patients without tuberculosis: How many are eligible for antiretroviral therapy in Karnataka, India?. <i>Journal of Epidemiology and Global Health</i> , 2017, 7, 11.	2.9	7
121	High HIV-1 Diversity and Prevalence of Transmitted Drug Resistance Among Antiretroviral-Naive HIV-Infected Pregnant Women from Rio de Janeiro, Brazil. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 68-73.	1.1	14
122	HIV care in Yangon, Myanmar; successes, challenges and implications for policy. <i>AIDS Research and Therapy</i> , 2017, 14, 10.	1.7	17
123	Using the multiphase optimization strategy (MOST) to optimize an HIV care continuum intervention for vulnerable populations: a study protocol. <i>BMC Public Health</i> , 2017, 17, 383.	2.9	46
124	HIV-1 strains belonging to large phylogenetic clusters show accelerated escape from integrase inhibitors in cell culture compared with viral isolates from singleton/small clusters. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2171-2183.	3.0	8
125	Effects of high CD4 cell counts on death and attrition among HIV patients receiving antiretroviral treatment: an observational cohort study. <i>Scientific Reports</i> , 2017, 7, 3129.	3.3	34
126	The Effect of Same-Day Observed Initiation of Antiretroviral Therapy on HIV Viral Load and Treatment Outcomes in a US Public Health Setting. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 44-51.	2.1	179
127	Association of Implementation of a Universal Testing and Treatment Intervention With HIV Diagnosis, Receipt of Antiretroviral Therapy, and Viral Suppression in East Africa. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2196.	7.4	116

#	ARTICLE	IF	CITATIONS
128	Moving from Public Health Failure to Opportunity. Journal of the International Association of Providers of AIDS Care, 2017, 16, 107-109.	1.5	1
129	Partnership agreements less likely among young gay and bisexual men in Australia – data from a national online survey of gay and bisexual men’s relationships. Sexual Health, 2017, 14, 355.	0.9	1
130	Combination antiretroviral therapy and cancer risk. Current Opinion in HIV and AIDS, 2017, 12, 12-19.	3.8	31
131	Virologic outcomes in early antiretroviral treatment: HPTN 052. HIV Clinical Trials, 2017, 18, 100-109.	2.0	20
132	Pathophysiology of ischaemic heart disease. Current Opinion in HIV and AIDS, 2017, 12, 548-553.	3.8	3
133	Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial. The Lancet Global Health, 2017, 5, e1080-e1089.	6.3	128
134	The costs of HIV treatment and care in Ghana. Aids, 2017, 31, 2279-2286.	2.2	7
135	Control of HIV epidemic: improve access to testing and ART. Lancet HIV, the, 2017, 4, e533-e534.	4.7	5
136	From intention to <sc>STI</sc> prevention: An online questionnaire on barriers and facilitators for discussing sexual risk behaviour among <sc>HIV</sc> nurses. Journal of Advanced Nursing, 2017, 73, 2953-2961.	3.3	3
137	Recent mobile health interventions to support medication adherence among HIV-positive MSM. Current Opinion in HIV and AIDS, 2017, 12, 432-441.	3.8	94
138	Treatment as Prevention: Characterization of Partner Infections in the HIV Prevention Trials Network 052 Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 112-116.	2.1	54
139	Antiretroviral Drug Use in a Cross-Sectional Population Survey in Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 158-165.	2.1	8
140	Optimal management of children on antiretroviral therapy (ART) in primary care: a quality improvement project. South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care, 2017, 59, 29-34.	0.6	1
141	Test-and-treat approach to HIV/AIDS: a primer for mathematical modeling. Theoretical Biology and Medical Modelling, 2017, 14, 16.	2.1	14
142	Potential for immune-driven viral polymorphisms to compromise antiretroviral-based preexposure prophylaxis for prevention of HIV-1 infection. Aids, 2017, 31, 1935-1943.	2.2	7
143	Mortality in patients with HIV-1 and tuberculosis co-infection in Rio de Janeiro, Brazil - associated factors and causes of death. BMC Infectious Diseases, 2017, 17, 373.	2.9	47
144	Immunological and virological characterization of HIV-1 viremia controllers in the North Region of Brazil. BMC Infectious Diseases, 2017, 17, 381.	2.9	11
145	Antiretroviral therapy related adverse effects: Can sub-Saharan Africa cope with the new ‘test and treat’ policy of the World Health Organization?. Infectious Diseases of Poverty, 2017, 6, 24.	3.7	32

#	ARTICLE	IF	CITATIONS
146	Nanoformulated Antiretrovirals for Penetration of the Central Nervous System: State of the Art. <i>Journal of NeuroImmune Pharmacology</i> , 2017, 12, 17-30.	4.1	18
147	Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance. <i>Virus Research</i> , 2017, 239, 1-9.	2.2	50
148	Comparing those diagnosed early versus late in their HIV infection: implications for public health. <i>International Journal of STD and AIDS</i> , 2017, 28, 693-701.	1.1	12
149	Principles of Management of HIV in the Industrialized World. , 2017, , 912-917.e2.		3
150	Antiviral Therapy. , 2017, , 918-926.e1.		1
151	Are partners of HIV-infected people being tested for HIV? A mixed-methods research from Gujarat, India. <i>Public Health Action</i> , 2017, 7, 46-54.	1.2	13
152	Pulmonary tuberculosis diagnostic practices among people living with the human immunodeficiency virus in Lesotho. <i>International Journal of Tuberculosis and Lung Disease</i> , 2017, 21, 1133-1138.	1.2	0
153	PrEP in Italy: The time may be ripe but who's paying the bill? A nationwide survey on physicians' attitudes towards using antiretrovirals to prevent HIV infection. <i>PLoS ONE</i> , 2017, 12, e0181433.	2.5	9
154	Delays in HIV diagnosis and associated factors among patients presenting with advanced disease at a tertiary care hospital in Beijing, China. <i>PLoS ONE</i> , 2017, 12, e0182335.	2.5	8
155	Status and methodology of publicly available national HIV care continua and 90-90-90 targets: A systematic review. <i>PLoS Medicine</i> , 2017, 14, e1002253.	8.4	88
156	Randomized trial of stopping or continuing ART among postpartum women with pre-ART CD4 ≥ 400 cells/mm ³ . <i>PLoS ONE</i> , 2017, 12, e0176009.	2.5	23
157	Treatment eligibility and retention in clinical HIV care: A regression discontinuity study in South Africa. <i>PLoS Medicine</i> , 2017, 14, e1002463.	8.4	60
158	Advanced Human Immunodeficiency Virus Disease at Diagnosis in Mozambique and Swaziland. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx156.	0.9	10
159	The role of family planning in achieving safe pregnancy for serodiscordant couples: commentary from the United States government's interagency task force on family planning and HIV service integration. <i>Journal of the International AIDS Society</i> , 2017, 20, 21312.	3.0	8
160	The Human Immunodeficiency Virus Care Continuum in China: 1985–2015. <i>Clinical Infectious Diseases</i> , 2018, 66, 833-839.	5.8	48
161	Sexual risk taking and the HIV care continuum in an online sample of men who have sex with men. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 921-929.	1.2	3
162	Avoidant Coping Mediates the Relationship Between Self-Efficacy for HIV Disclosure and Depression Symptoms Among Men Who Have Sex with Men Newly Diagnosed with HIV. <i>AIDS and Behavior</i> , 2018, 22, 3130-3140.	2.7	16
163	Care continuum entry interventions. <i>Aids</i> , 2018, 32, 407-417.	2.2	14

#	ARTICLE	IF	CITATIONS
164	Impact of early antiretroviral therapy eligibility on HIV acquisition. <i>Aids</i> , 2018, 32, 635-643.	2.2	13
165	HIV Drug Resistance in Adults Receiving Early vs. Delayed Antiretroviral Therapy: HPTN 052. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 484-491.	2.1	10
166	The effect of partner HIV status on motivation to take antiretroviral and isoniazid preventive therapies: a conjoint analysis. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 1298-1305.	1.2	5
167	Treatment and prevention of HIV infection with long-acting antiretrovirals. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 507-517.	3.1	38
168	Suboptimal immune recovery during antiretroviral therapy with sustained HIV suppression in sub-Saharan Africa. <i>Aids</i> , 2018, 32, 1043-1051.	2.2	47
169	High Prevalence of Drug Resistance Mutations Among Patients Failing First-Line Antiretroviral Therapy and Predictors of Virological Response 24 Weeks After Switch to Second-Line Therapy in São Paulo State, Brazil. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 156-164.	1.1	6
170	Precision medicine for HIV: where are we?. <i>Pharmacogenomics</i> , 2018, 19, 145-165.	1.3	16
171	Strength in Amalgamation: Newer Combination Agents for HIV and Implications for Practice. <i>Pharmacotherapy</i> , 2018, 38, 86-107.	2.6	6
172	High CXCL10/IP-10 levels are a hallmark in the clinical evolution of the HIV infection. <i>Infection, Genetics and Evolution</i> , 2018, 57, 51-58.	2.3	30
173	“We Deserve Better!” Perceptions of HIV Testing Campaigns Among Black and Latino MSM in New York City. <i>Archives of Sexual Behavior</i> , 2018, 47, 289-297.	1.9	25
174	Factors Influencing the Initiation of Treatment after the Diagnosis of Korean Patients with HIV. <i>Journal of Korean Academy of Community Health Nursing</i> , 2018, 29, 279.	0.4	1
175	Impact of "test and treat" recommendations on eligibility for antiretroviral treatment: Cross sectional population survey data from three high HIV prevalence countries. <i>PLoS ONE</i> , 2018, 13, e0207656.	2.5	16
176	Presenting national HIV/AIDS and sexually transmitted disease research in Brazil. <i>Medicine (United States)</i> , 2018, 97, S3-S8.	1.0	49
177	Prevalence estimates of HIV, syphilis, hepatitis B and C among female sex workers (FSW) in Brazil, 2016. <i>Medicine (United States)</i> , 2018, 97, S3-S8.	1.0	48
178	Attrition Across the HIV Cascade of Care Among a Diverse Cohort of Women Living With HIV in Canada. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 226-236.	2.1	39
179	HIV-1 update 2018. <i>Pharmacy Today</i> , 2018, 24, 51-69.	0.0	1
180	Brief Report: Intimate Partner Violence and Antiretroviral Therapy Initiation Among Female Sex Workers Newly Diagnosed With HIV in Zambia: A Prospective Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 435-439.	2.1	11
181	Duration of Human Immunodeficiency Virus Infection at Diagnosis among New Human Immunodeficiency Virus Cases in Dehong, Yunnan, China, 2008-2015. <i>Chinese Medical Journal</i> , 2018, 131, 1936-1943.	2.3	9

#	ARTICLE	IF	CITATIONS
182	Incidence, Predictors, and Outcomes of Implantable Cardioverter-Defibrillator Discharge Among People Living With HIV. <i>Journal of the American Heart Association</i> , 2018, 7, e009857.	3.7	11
183	Tuberculosis burden on AIDS in Brazil: A study using linked databases. <i>PLoS ONE</i> , 2018, 13, e0207859.	2.5	7
184	Diagnosis of Human Immunodeficiency Virus Infection. <i>Clinical Microbiology Reviews</i> , 2018, 32, .	13.6	51
185	Integrating HIV care and treatment into tuberculosis clinics in Lusaka, Zambia: results from a before-after quasi-experimental study. <i>BMC Infectious Diseases</i> , 2018, 18, 536.	2.9	19
186	The Dark Side of Female HIV Patient Care: Sexual and Reproductive Health Risks in Pre- and Post-Clinical Treatments. <i>Journal of Clinical Medicine</i> , 2018, 7, 402.	2.4	6
187	Comparative evaluation of the Geenius HIV 1/2 Confirmatory Assay and the HIV-1 and HIV-2 Western blots in the Japanese population. <i>PLoS ONE</i> , 2018, 13, e0198924.	2.5	11
188	Acute HIV Infection and CD4/CD8 Ratio Normalization After Antiretroviral Therapy Initiation. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 510-518.	2.1	29
189	Impact of a massive earthquake on adherence to antiretroviral therapy, mental health, and treatment failure among people living with HIV in Nepal. <i>PLoS ONE</i> , 2018, 13, e0198071.	2.5	9
190	Influence of geographic origin on AIDS and serious non-AIDS morbidity/mortality during cART among heterosexual HIV-infected men and women in France. <i>PLoS ONE</i> , 2018, 13, e0205385.	2.5	1
191	Absolute CD4+ T cell count overstate immune recovery assessed by CD4+/CD8+ ratio in HIV-infected patients on treatment. <i>PLoS ONE</i> , 2018, 13, e0205777.	2.5	13
192	High Prevalence of Late-Stage Disease in Newly Diagnosed Human Immunodeficiency Virus Patients in Sierra Leone. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy208.	0.9	18
193	“Hurdles on the path to 90-90-90 and beyond”: Qualitative analysis of barriers to engagement in HIV care among individuals in rural East Africa in the context of test-and-treat. <i>PLoS ONE</i> , 2018, 13, e0202990.	2.5	54
194	Antiretroviral Therapy and Mortality in Rural South Africa: A Comparison of Causal Modeling Approaches. <i>American Journal of Epidemiology</i> , 2018, 187, 1772-1779.	3.4	3
195	Closing the delivery gap. <i>International Journal of Health Care Quality Assurance</i> , 2018, 31, 327-336.	0.9	0
196	Improving Estimation of HIV Viral Suppression in the United States: A Method to Adjust HIV Surveillance Estimates From the Medical Monitoring Project Using Cohort Data. <i>American Journal of Epidemiology</i> , 2018, 187, 1962-1969.	3.4	2
197	Does Economic Strengthening Improve Viral Suppression Among Adolescents Living with HIV? Results From a Cluster Randomized Trial in Uganda. <i>AIDS and Behavior</i> , 2018, 22, 3763-3772.	2.7	61
198	Rapid initiation of antiretroviral therapy for people living with HIV. <i>The Cochrane Library</i> , 0, , .	2.8	3
199	The effect of mobility on HIV-related healthcare access and use for female sex workers: A systematic review. <i>Social Science and Medicine</i> , 2018, 211, 261-273.	3.8	21

#	ARTICLE	IF	CITATIONS
200	Do HIV treatment eligibility expansions crowd out the sickest? Evidence from rural South Africa. <i>Tropical Medicine and International Health</i> , 2018, 23, 968-979.	2.3	11
201	Looking for Novel Capsid Protein Multimerization Inhibitors of Feline Immunodeficiency Virus. <i>Pharmaceuticals</i> , 2018, 11, 67.	3.8	7
202	Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2112-2119.	3.0	15
204	Current Treatment Options for HIV Elite Controllers: a Review. <i>Current Treatment Options in Infectious Diseases</i> , 2018, 10, 302-309.	1.9	12
205	Weighing the Evidence of Efficacy of Oral PrEP for HIV Prevention in Women in Southern Africa. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 645-656.	1.1	23
206	Substance Use and Adherence to Antiretroviral Therapy: What Is Known and What Is Unknown. <i>Current Infectious Disease Reports</i> , 2018, 20, 36.	3.0	25
207	Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain. <i>PLoS ONE</i> , 2018, 13, e0190487.	2.5	100
208	Nationwide Cohort Study of Antiretroviral Therapy Timing: Treatment Dropout and Virological Failure in China, 2011-2015. <i>Clinical Infectious Diseases</i> , 2019, 68, 43-50.	5.8	21
209	The Role of Religious Service Attendance, Psychosocial and Behavioral Determinants of Antiretroviral Therapy (ART) Adherence: Results from HPTN 063 Cohort Study. <i>AIDS and Behavior</i> , 2019, 23, 459-474.	2.7	6
210	Missed opportunities for earlier diagnosis of human immunodeficiency virus infection among adults presenting to Auckland District Health Board hospital services. <i>Internal Medicine Journal</i> , 2019, 49, 495-501.	0.8	4
211	Undetectable = Untransmittable and Your Health: The Personal Benefits of Early and Continuous Therapy for HIV Infection. <i>Journal of Infectious Diseases</i> , 2019, 219, 173-176.	4.0	14
212	Rapid initiation of antiretroviral therapy in those with newly diagnosed HIV infection in London, UK. <i>HIV Medicine</i> , 2019, 20, 699-703.	2.2	11
213	Feasibility of community-based HIV self-screening in South Africa: a demonstration project. <i>BMC Public Health</i> , 2019, 19, 898.	2.9	17
214	Protocol for a randomized clinical trial exploring the effect of antimicrobial agents on the penile microbiota, immunology and HIV susceptibility of Ugandan men. <i>Trials</i> , 2019, 20, 443.	1.6	7
215	Using the Lifeworld Approach to Improve HIV Testing. <i>Social Work in Public Health</i> , 2019, 34, 542-555.	1.4	1
216	Effect of HIV infection on TB treatment outcomes and time to mortality in two urban hospitals in Ghana-a retrospective cohort study. <i>Pan African Medical Journal</i> , 2019, 32, 206.	0.8	5
217	How Monocytes Contribute to Increased Risk of Atherosclerosis in Virologically-Suppressed HIV-Positive Individuals Receiving Combination Antiretroviral Therapy. <i>Frontiers in Immunology</i> , 2019, 10, 1378.	4.8	25
218	Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d'Ivoire: A model-based analysis. <i>PLoS ONE</i> , 2019, 14, e0219068.	2.5	5

#	ARTICLE	IF	CITATIONS
219	Life expectancy and disparities in survival among HIV-infected people receiving antiretroviral therapy: an observational cohort study in Kathmandu, Nepal. <i>BMJ Global Health</i> , 2019, 4, e001319.	4.7	8
220	Distribution of advanced HIV disease from three high HIV prevalence settings in Sub-Saharan Africa: a secondary analysis data from three population-based cross-sectional surveys in Eshowe (South) Tj ETQq1 1 0.784314 rgt / Overlock 10		
221	Causes of hospitalization and predictors of HIV-associated mortality at the main referral hospital in Sierra Leone: a prospective study. <i>BMC Public Health</i> , 2019, 19, 1320.	2.9	31
222	Gender Norms and HIV Testing/Treatment Uptake: Evidence from a Large Population-Based Sample in South Africa. <i>AIDS and Behavior</i> , 2019, 23, 162-171.	2.7	29
223	Progress and challenges in China's free ART programme. <i>Lancet HIV</i> , 2019, 6, e8-e9.	4.7	6
224	Research priorities to inform "Treat All" policy implementation for people living with HIV in sub-Saharan Africa: a consensus statement from the International epidemiology Databases to Evaluate AIDS (IeDEA). <i>Journal of the International AIDS Society</i> , 2019, 22, e25218.	3.0	32
225	Intention to initiate antiretroviral therapy (ART) among people living with HIV in China under the scaling-up of ART: the role of healthcare workers' recommendations. <i>BMC Health Services Research</i> , 2019, 19, 314.	2.2	6
226	HIV-1 DNA sequence diversity and evolution during acute subtype C infection. <i>Nature Communications</i> , 2019, 10, 2737.	12.8	51
227	HIV testing and the HIV care continuum among sub-Saharan African men who have sex with men and transgender women screened for participation in HPTN 075. <i>PLoS ONE</i> , 2019, 14, e0217501.	2.5	38
228	Screening for HIV Infection in Asymptomatic, Nonpregnant Adolescents and Adults. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 2337.	7.4	12
229	Screening for HIV Infection. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 2326.	7.4	137
230	Increased monocyte activation with age among HIV-infected long term non-progressor children: implications for early treatment initiation. <i>HIV Medicine</i> , 2019, 20, 513-522.	2.2	2
231	Losses to follow-up of HIV-infected people in the Spanish VACH cohort over the period between 2013 and 2014: The importance of sociodemographic factors. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , 2019, 37, 361-366.	0.3	0
232	Systematic Review and Meta-analysis of Treatment Interruptions in Human Immunodeficiency Virus (HIV) Type 1-infected Patients Receiving Antiretroviral Therapy: Implications for Future HIV Cure Trials. <i>Clinical Infectious Diseases</i> , 2020, 70, 1406-1417.	5.8	5
233	Late Onset of Antiretroviral Therapy in Adults Living with HIV in an Urban Area in Brazil: Prevalence and Risk Factors. <i>Journal of Tropical Medicine</i> , 2019, 2019, 1-8.	1.7	16
234	Physician Mistrust, Medical System Mistrust, and Perceived Discrimination: Associations with HIV Care Engagement and Viral Load. <i>AIDS and Behavior</i> , 2019, 23, 2859-2869.	2.7	34
235	Late HIV Diagnosis but Earlier Antiretroviral Treatment Initiation in Northwest Spain: Impact of Current Treatment Guidelines. <i>Journal of the International Association of Providers of AIDS Care</i> , 2019, 18, 232595821882194.	1.5	3
236	Population size and self-reported characteristics and sexual preferences of men-who-have-sex-with-men (MSM) in Germany based on social network data. <i>PLoS ONE</i> , 2019, 14, e0212175.	2.5	4

#	ARTICLE	IF	CITATIONS
237	People who inject drugs remain hard-to-reach population across all HIV continuum stages in Central, Eastern and South Eastern Europe – data from Euro-guidelines in Central and Eastern Europe Network. <i>Infectious Diseases</i> , 2019, 51, 277-286.	2.8	20
238	Challenges and opportunities to prevent tuberculosis in people living with HIV in low-income countries. <i>International Journal of Tuberculosis and Lung Disease</i> , 2019, 23, 241-251.	1.2	16
240	Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps. <i>HIV Medicine</i> , 2019, 20, 3-11.	2.2	68
241	Combining surveillance systems to investigate local trends in tuberculosis-HIV co-infection. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2019, 31, 1311-1318.	1.2	7
242	“Not Like Taking Chocolates”: Factors Influencing the Feasibility and Sustainability of Universal Test and Treat in Correctional Health Systems in Zambia and South Africa. <i>Global Health, Science and Practice</i> , 2019, 7, 189-202.	1.7	13
243	HIV/AIDS, STIs and viral hepatitis in Brazil: epidemiological trends. <i>Revista Brasileira De Epidemiologia</i> , 2019, 22, e190001.	0.8	17
244	Rapid initiation of antiretroviral therapy for people living with HIV. <i>The Cochrane Library</i> , 2019, 6, CD012962.	2.8	43
245	Global, regional and country-level 90-90-90 estimates for 2018. <i>Aids</i> , 2019, 33, S213-S226.	2.2	123
246	Cost-effectiveness of increased HIV testing among MSM in The Netherlands. <i>Aids</i> , 2019, 33, 1807-1817.	2.2	6
247	When Global ART Budgets Cannot Cover All Patients, Who Should Be Eligible?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 134-137.	2.1	5
248	A generalizable method for estimating duration of HIV infections using clinical testing history and HIV test results. <i>Aids</i> , 2019, 33, 1231-1240.	2.2	18
250	Antiretroviral treatment indications and adherence to the German-Austrian treatment initiation guidelines in the German ClinSurv HIV Cohort between 1999 and 2016. <i>Infection</i> , 2019, 47, 247-255.	4.7	9
251	Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Negative for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004-2014. <i>HIV Medicine</i> , 2019, 20, 99-109.	2.2	19
252	Experiences of the HIV Cascade of Care Among Indigenous Peoples: A Systematic Review. <i>AIDS and Behavior</i> , 2019, 23, 984-1003.	2.7	26
253	Positive Strategies to Enhance Problem-Solving Skills (STEPS): A Pilot Randomized, Controlled Trial of a Multicomponent, Technology-Enhanced, Customizable Antiretroviral Adherence Intervention for HIV-Infected Adolescents and Young Adults. <i>AIDS Patient Care and STDs</i> , 2019, 33, 21-24.	2.5	17
254	Órdenes de seguimiento de personas con infecci3n por el VIH en la cohorte espa±ola VACH en el periodo 2013-2014: importancia de los factores sociodemogrÁficos. <i>Enfermedades Infecciosas Y MicrobiologÁa ClÁnica</i> , 2019, 37, 361-366.	0.5	6
255	Impact of initiation of combination antiretroviral therapy according to the WHO recommendations on the survival of HIV-positive patients in Taiwan. <i>Journal of Microbiology, Immunology and Infection</i> , 2020, 53, 936-945.	3.1	14
256	Treatment as prevention (TasP) and perceived sexual changes in behavior among HIV-positive persons: a French survey in infectious diseases departments in Paris. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 811-817.	1.2	2

#	ARTICLE	IF	CITATIONS
257	Prevention of HIV Transmission and the HPTN 052 Study. <i>Annual Review of Medicine</i> , 2020, 71, 347-360.	12.2	25
258	Review of HIV testing recommendations in Australian specialty guidelines for HIV indicator conditions: a missed opportunity for recommending testing?. <i>Internal Medicine Journal</i> , 2020, 50, 293-298.	0.8	8
259	Impact of frequent testing on the transmission of HIV and <i>N. gonorrhoeae</i> among men who have sex with men: a mathematical modelling study. <i>Sexually Transmitted Infections</i> , 2020, 96, 361-367.	1.9	6
260	Rapid Initiation of Antiretroviral Therapy Following Diagnosis of Human Immunodeficiency Virus Among Patients with Commercial Insurance Coverage. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 129-141.	0.9	2
261	MicroRNAs and exosomes: key players in HIV pathogenesis. <i>HIV Medicine</i> , 2020, 21, 246-278.	2.2	57
262	Same-day antiretroviral treatment (ART) initiation and associated factors among HIV positive people in Northwest Ethiopia: baseline characteristics of prospective cohort. <i>Archives of Public Health</i> , 2020, 78, 87.	2.4	10
263	Towards achieving the 90-90-90 HIV targets: results from the south African 2017 national HIV survey. <i>BMC Public Health</i> , 2020, 20, 1375.	2.9	70
264	Effect of a multi-dimensional case management model on anti-retroviral therapy-related outcomes among people living with human immunodeficiency virus in Beijing, China. <i>BMC Infectious Diseases</i> , 2020, 20, 489.	2.9	3
265	Acceptability of HIV self-testing is low among men who have sex with men who have not tested for HIV: a study with respondent-driven sampling in Brazil. <i>BMC Infectious Diseases</i> , 2020, 20, 865.	2.9	11
266	Toward Universal HIV Treatment in Haiti: Time Trends in ART Retention After Expanded ART Eligibility in a National Cohort From 2011 to 2017. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, 153-161.	2.1	11
267	Early access to antiretroviral therapy versus standard of care among HIV-positive participants in Eswatini in the public health sector: the MaxART stepped-wedge randomized controlled trial. <i>Journal of the International AIDS Society</i> , 2020, 23, e25610.	3.0	20
268	First-line HIV treatment outcomes following the introduction of integrase inhibitors in UK guidelines. <i>Aids</i> , 2020, 34, 1823-1831.	2.2	11
269	Interprofessional collaboration associated with frequency of life-saving links to HIV continuum of care services in the urban environment of Newark, New Jersey. <i>BMC Health Services Research</i> , 2020, 20, 1014.	2.2	1
270	Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials. <i>AIDS and Behavior</i> , 2020, 24, 3473-3481.	2.7	27
271	Behavioural, social and structural-level risk factors for developing AIDS among HIV-positive people who use injection drugs in a Canadian setting, 1996-2017. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 1262-1267.	1.2	1
272	Getting to 90-90-90: Experiences from the MaxART Early Access to ART for All (EAAA) Trial in Eswatini. <i>Current HIV/AIDS Reports</i> , 2020, 17, 324-332.	3.1	5
273	African potato (<i>Hypoxis hemerocallidea</i>): a systematic review of its chemistry, pharmacology and ethno medicinal properties. <i>BMC Complementary Medicine and Therapies</i> , 2020, 20, 182.	2.7	10
274	Estimating the probability of diagnosis within 1 year of HIV acquisition. <i>Aids</i> , 2020, 34, 1075-1080.	2.2	10

#	ARTICLE	IF	CITATIONS
275	Implementation opportunities and challenges identified by key stakeholders in scaling up HIV Treatment as Prevention in British Columbia, Canada: a qualitative study. <i>Implementation Science Communications</i> , 2020, 1, 54.	2.2	4
276	<p>HIV Treatment Outcomes Among Patients Initiated on Antiretroviral Therapy Pre and Post-Universal Test and Treat Guidelines in South Africa</p>. <i>Therapeutics and Clinical Risk Management</i> , 2020, Volume 16, 169-180.	2.0	25
277	Enrollment and transition challenges in the International Maternal Pediatric and Adolescent AIDS Clinical Trials (IMPAACT) network's PROMISE trial for resource-limited regions. <i>Clinical Trials</i> , 2020, 17, 437-447.	1.6	5
278	A community-based HIV counselling and testing programme found a decreasing proportion of new HIV testers in South Africa. <i>African Journal of AIDS Research</i> , 2020, 19, 34-39.	0.9	1
279	HIV Treatment Knowledge in the Context of "Treatment as Prevention" (TasP). <i>AIDS and Behavior</i> , 2020, 24, 2984-2994.	2.7	10
280	Estimated dates of detectable infection (EDDIs) as an improvement upon Fiebig staging for HIV infection dating. <i>Epidemiology and Infection</i> , 2020, 148, e53.	2.1	5
281	Current and future treatments for tuberculosis. <i>BMJ</i> , The, 2020, 368, m216.	6.0	43
283	The global meningitis genome partnership. <i>Journal of Infection</i> , 2020, 81, 510-520.	3.3	13
284	Continuous quality monitoring in the field: an evaluation of the performance of the Fio Deki Reader, for rapid HIV testing in South Africa. <i>BMC Infectious Diseases</i> , 2020, 20, 320.	2.9	4
285	Association of antiretroviral therapy with anal high-risk human papillomavirus, anal intraepithelial neoplasia, and anal cancer in people living with HIV: a systematic review and meta-analysis. <i>Lancet HIV</i> , the, 2020, 7, e262-e278.	4.7	46
286	Frequency and Predictors of HIV-Related Cognitive Impairment in East Africa: The Africa Cohort Study (AFRICOS). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 157-164.	2.1	9
287	Determinants of loss to follow-up among HIV positive patients receiving antiretroviral therapy in a test and treat setting: A retrospective cohort study in Masaka, Uganda. <i>PLoS ONE</i> , 2020, 15, e0217606.	2.5	35
288	Development and Validation of a Sociodemographic and Behavioral Characteristics-Based Risk-Score Algorithm for Targeting HIV Testing Among Adults in Kenya. <i>AIDS and Behavior</i> , 2021, 25, 297-310.	2.7	10
290	Using longitudinal genetic-network study to understand HIV treatment-as-prevention. <i>Aids</i> , 2021, 35, 947-955.	2.2	16
291	OUP accepted manuscript. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2666-2674.	3.0	0
292	Maternidade e HIV: Continuidade do Tratamento e Adesão em Mulheres após o Parto. <i>Psico-USF</i> , 2021, 26, 53-65.	0.2	0
293	A randomized prospective study to assess health-related quality-of-life outcomes of antiretroviral therapy in human immunodeficiency virus-positive adults. <i>Indian Journal of Sexually Transmitted Diseases and AIDS</i> , 2021, 42, 50.	0.3	8
294	Targeted HIV screening in the emergency department. <i>Internal and Emergency Medicine</i> , 2021, 16, 1273-1287.	2.0	3

#	ARTICLE	IF	CITATIONS
295	“Dispense antiretrovirals daily” restructuring the delivery of HIV services to optimize antiretroviral initiation among men in Malawi. PLoS ONE, 2021, 16, e0247409.	2.5	3
296	The Role of Targeted HIV Screening in the Emergency Department: A Scoping Review. Current HIV Research, 2021, 19, 106-120.	0.5	3
297	Quality of life and associated factors among HIV positive patients after completion of treatment for Cryptococcal meningitis. PLoS Neglected Tropical Diseases, 2021, 15, e0008983.	3.0	1
298	Epidemiological factors associated with recent HIV infection among newly-diagnosed cases in Singapore, 2013–2017. BMC Public Health, 2021, 21, 430.	2.9	6
299	Dolutegravir Plus Lamivudine Two-Drug Regimen: Safety, Efficacy and Diagnostic Considerations for Its Use in Real-Life Clinical Practice—A Refined Approach in the COVID-19 Era. Diagnostics, 2021, 11, 809.	2.6	4
300	Resilience revisited: AIDS and resilience among a Yi ethnic minority in Southwest China. Theory and Psychology, 2022, 32, 38-60.	1.2	4
301	Assessing comorbidities and survival in HIV-infected and uninfected matched Medicare enrollees. Aids, 2021, 35, 1667-1675.	2.2	11
302	Baseline CD4 count and the time interval between the initial HIV infection and diagnosis among PLHIV in Bhutan. Immunity, Inflammation and Disease, 2021, 9, 883-890.	2.7	5
303	Trends in knowledge of HIV status and efficiency of HIV testing services in sub-Saharan Africa, 2000–2020: a modelling study using survey and HIV testing programme data. Lancet HIV, 2021, 8, e284-e293.	4.7	82
304	HIV Infection: Time from Diagnosis to Initiation of Antiretroviral Therapy in Portugal, a Multicentric Study. Healthcare (Switzerland), 2021, 9, 797.	2.0	4
305	Factors Associated with Never Testing for HIV: Directions for Targeted Testing Interventions Among Men Who Have Sex with Men. AIDS Patient Care and STDs, 2021, 35, 204-210.	2.5	2
306	Prevalence of transmitted HIV-1 drug resistance among treatment-naive individuals in China, 2000-2016. Archives of Virology, 2021, 166, 2451-2460.	2.1	10
307	Persons living with HIV in sero-discordant partnerships experience improved HIV care engagement compared with persons living with HIV in sero-concordant partnerships: a cross-sectional analysis of four African countries. AIDS Research and Therapy, 2021, 18, 43.	1.7	3
308	Durable Viral Suppression Among People with HIV and Problem Substance Use in the Era of Universal Antiretroviral Treatment. AIDS and Behavior, 2022, 26, 385-396.	2.7	5
309	Quality of life among older Chinese people living with HIV/AIDS: a cross-sectional study in Hunan. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2022, 116, 213-221.	1.8	3
310	Abrupt and altered cell-type specific DNA methylation profiles in blood during acute HIV infection persists despite prompt initiation of ART. PLoS Pathogens, 2021, 17, e1009785.	4.7	12
311	Nationwide surveillance of AIDS-defining illnesses among HIV patients in Japan from 1995 to 2017. PLoS ONE, 2021, 16, e0256452.	2.5	6
312	Late diagnosis of HIV infection and its associated factors in Shiraz, Southern Iran: a retrospective study. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2022, 34, 1321-1329.	1.2	6

#	ARTICLE	IF	CITATIONS
313	HIV diagnosis period influences ART initiation: findings from a prospective cohort study in China. <i>AIDS Research and Therapy</i> , 2021, 18, 59.	1.7	2
314	Evaluation of Broadly Neutralizing Antibody Sensitivity by Genotyping and Phenotyping for Qualifying Participants to HIV Clinical Trials. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 88, 61-69.	2.1	6
315	Understanding the Risk of Human Immunodeficiency Virus (HIV) Virologic Failure in the Era of Undetectable Equals Untransmittable. <i>AIDS and Behavior</i> , 2021, 25, 2259-2265.	2.7	5
316	A network-based model to explore the role of testing in the epidemiological control of the COVID-19 pandemic. <i>BMC Infectious Diseases</i> , 2021, 21, 58.	2.9	26
317	Factors Associated With Poor Linkage to Human Immunodeficiency Virus Care Among Index Clients and Sex Partners Receiving Human Immunodeficiency Virus Assisted Partner Services in Kenya. <i>Sexually Transmitted Diseases</i> , 2020, 47, 610-616.	1.7	1
318	Treatment guidelines and early loss from care for people living with HIV in Cape Town, South Africa: A retrospective cohort study. <i>PLoS Medicine</i> , 2017, 14, e1002434.	8.4	16
319	Risk Factors for Delayed Entrance into Care after Diagnosis among Patients with Late-Stage HIV Disease in Southern Vietnam. <i>PLoS ONE</i> , 2014, 9, e108939.	2.5	27
320	Australian Gay and Bisexual Men's Attitudes to HIV Treatment as Prevention in Repeated, National Surveys, 2011-2013. <i>PLoS ONE</i> , 2014, 9, e112349.	2.5	14
321	Beyond Risk Compensation: Clusters of Antiretroviral Treatment (ART) Users in Sexual Networks Can Modify the Impact of ART on HIV Incidence. <i>PLoS ONE</i> , 2016, 11, e0163159.	2.5	9
322	Proportion and factors associated with recent HIV infection in a cohort of patients seen for care in Italy over 1996-2014: Data from the ICONA Foundation Study cohort. <i>PLoS ONE</i> , 2017, 12, e0189045.	2.5	4
323	Assessing the health status and mortality of older people over 65 with HIV. <i>PLoS ONE</i> , 2020, 15, e0241833.	2.5	21
324	Effectiveness and Cost-Effectiveness of Treatment as Prevention for HIV. , 2017, , 91-111.		4
325	Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infection—Results of Italian Network of ACuTe HIV Infection (INACTION) Retrospective Study. <i>Pathogens and Immunity</i> , 2020, 5, 8.	3.1	16
326	Point-of-care HIV tests done by peers, Brazil. <i>Bulletin of the World Health Organization</i> , 2016, 94, 626-630.	3.3	10
327	The importance of assessing self-reported HIV status in bio-behavioural surveys. <i>Bulletin of the World Health Organization</i> , 2016, 94, 605-612.	3.3	21
328	AMMI Canada position statement: The use of early antiretroviral therapy in HIV-infected persons. <i>Jammi</i> , 2017, 1, 1-11.	0.5	2
329	Prevalence and Factors Associated with Virologic Failure among People Living with HIV (PLHIV) Monitored in a Decentralized Health Care Facility. <i>Advances in Infectious Diseases</i> , 2019, 09, 226-237.	0.2	3
330	Incidence and predictors of attrition among patients receiving ART in eastern Zimbabwe before, and after the introduction of universal "treat-all" policies: A competing risk analysis. <i>PLOS Global Public Health</i> , 2021, 1, e0000006.	1.6	3

#	ARTICLE	IF	CITATIONS
331	Characteristics of new HIV diagnoses over 1995â€“2019: A clinic-based study in MontrÃ©al, Canada. PLoS ONE, 2021, 16, e0258383.	2.5	4
332	Antiretroviral Therapy: When to Start. , 2015, , 1-8.		0
333	HIV prevention & treatment - Reasons to rejoice & remain vigilant. Indian Journal of Medical Research, 2015, 142, 633.	1.0	1
334	The Impact of Human Immunodeficiency Virus (HIV) and Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) on Male and Female Fertility. , 2016, , 1-30.		0
335	The Odyssey of Linking to and Staying in HIV Care among Male Sex Workers in Peru. Journal of HIV and AIDS, 2017, 3, .	0.1	4
336	Antiretroviral Therapy: When to Start. , 2018, , 106-113.		0
338	Strategies for Progress. , 2019, , 3-43.		0
339	A prospective study on impact of early initiation of antiretroviral therapy in human immunodeficiency virus-positive adults on immunological status and adverse events. Journal of Global Infectious Diseases, 2019, 11, 73.	0.5	6
340	Persons living with HIV continue to present late for care: A trend analysis from 2011 to 2015. Indian Journal of Sexually Transmitted Diseases and AIDS, 2019, 40, 133.	0.3	1
342	The Revolution of HIV Testing. , 2020, , 251-268.		2
343	Ethics of theÂHIV/AIDS Response. , 2020, , 375-391.		0
346	Epidemiology of HIV Infection in Communities of Color in the United States. , 2021, , 15-49.		1
347	HIV care continuum among cisgender and transgender women sex workers in Greater Kuala Lumpur, Malaysia. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2021, , 1-7.	1.2	2
348	Antiretroviral Therapy (ART)-related Knowledge Seeking among People Living with HIV (PLHIV) in China: Role of Information & Communication Technology (ICT). Libri, 2020, 70, 197-211.	0.8	2
350	Determinants of two-year mortality among HIV positive patients with Cryptococcal meningitis initiating standard antifungal treatment with or without adjunctive dexamethasone in Uganda. PLoS Neglected Tropical Diseases, 2020, 14, e0008823.	3.0	4
351	No Increase in HIV Drug Resistance Mutations among Injecting Drug Users on Methadone Maintenance Therapy: A Prospective Cohort Study. Current HIV Research, 2020, 18, 362-372.	0.5	0
352	Factors associated with HIV viral load suppression on antiretroviral therapy in Vietnam. Journal of Virus Eradication, 2016, 2, 94-101.	0.5	30
353	Adverse reactions to antiretroviral therapy: a prevalent concern. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2017, 41, e84.	1.1	1

#	ARTICLE	IF	CITATIONS
354	Access to oral health care for people living with HIV/AIDS attending a community-based program. Canadian Journal of Dental Hygiene, 2020, 54, 7-15.	0.4	2
355	Accelerating Sustainable Development Goals for South African adolescents from high HIV prevalence areas: a longitudinal path analysis. BMC Medicine, 2021, 19, 263.	5.5	4
356	Characteristics and Sexual Risk Behavior of Men Who Never Tested for HIV in Zambia. American Journal of Men's Health, 2021, 15, 155798832110633.	1.6	2
357	HIV and STI prevalence and testing history among men who have sex with men in Hanoi, Vietnam. International Journal of STD and AIDS, 2021, , 095646242110601.	1.1	3
358	HIV incidence estimates by sex and age group in the population aged 15 years or over, Brazil, 1986-2018. Revista Da Sociedade Brasileira De Medicina Tropical, 2022, 55, e0231.	0.9	10
359	Linkage Rates of Newly Diagnosed and Previously Positive Patients After Routine HIV Screening in the Adult Emergency Department at University Hospital in Newark, New Jersey. AIDS Patient Care and STDs, 2022, 36, 51-54.	2.5	0
360	Patients' and Providers' Views on Optimal Evidence-Based and Scalable Interventions for Individuals at High Risk of HIV Treatment Failure: Sequential Explorations Among Key Stakeholders in Cape Town, South Africa. AIDS and Behavior, 2022, 26, 2783-2797.	2.7	3
361	Testing and healthcare seeking behavior preceding HIV diagnosis among migrant and non-migrant individuals living in the Netherlands: Directions for early-case finding. PLoS ONE, 2022, 17, e0264435.	2.5	3
362	"I need time to start antiretroviral therapy": understanding reasons for delayed ART initiation among people diagnosed with HIV in Lusaka, Zambia. Annals of Medicine, 2022, 54, 830-836.	3.8	7
363	Testing modality associated with fast-track ART initiation in Botswana. Tropical Medicine and International Health, 2022, , .	2.3	1
364	Characteristics of users of HIV self-testing in Kenya, outcomes, and factors associated with use: results from a population-based HIV impact assessment, 2018. BMC Public Health, 2022, 22, 643.	2.9	3
365	Early versus delayed antiretroviral therapy based on genotypic resistance test: Results from a large retrospective cohort study. Journal of Medical Virology, 2022, , .	5.0	1
366	British HIV Association guidelines for the management of HIV. HIV Medicine, 2021, 22, 1-29.	2.2	5
368	Knowledge and risk practices related to HIV infection in the general population, young men, and MSM in three Brazilian cities in 2019. Cadernos De Saude Publica, 2022, 38, .	1.0	1
370	Impact of low-level viremia with drug resistance on CD4 cell counts among people living with HIV on antiretroviral treatment in China. BMC Infectious Diseases, 2022, 22, 426.	2.9	4
371	Is There Risk Compensation among HIV Infected Youth and Adults 15 Years and Older on Antiretroviral Treatment in South Africa? Findings from the 2017 National HIV Prevalence, Incidence, Behaviour and Communication Survey. International Journal of Environmental Research and Public Health, 2022, 19, 6156.	2.6	5
372	Willingness of health care providers to offer HIV self-testing from specialized HIV care services in the northeast of Brazil. BMC Health Services Research, 2022, 22, .	2.2	3
373	Viral load monitoring for people living with HIV in the era of test and treat: progress made and challenges ahead - a systematic review. BMC Public Health, 2022, 22, .	2.9	11

#	ARTICLE	IF	CITATIONS
374	Factors associated with testing for HIV and other sexually transmitted infections in men who have sex with men and transgender women in Bangkok, Thailand. <i>AIDS Research and Therapy</i> , 2022, 19, .	1.7	2
375	Evidence and implication of interventions across various socioecological levels to address HIV testing uptake among men who have sex with men in the United States: A systematic review. <i>SAGE Open Medicine</i> , 2022, 10, 205031212211071.	1.8	2
376	Biomarkers in Anal Cancer: Current Status in Diagnosis, Disease Progression and Therapeutic Strategies. <i>Biomedicines</i> , 2022, 10, 2029.	3.2	3
377	Adherence to Antiretroviral Therapy and Its Predictive Factors Among People Living with HIV in China: A Behavioral Theory-Based Prospective Cohort Study. <i>International Journal of Behavioral Medicine</i> , 0, , .	1.7	1
379	Diagnosis and treatment of tuberculosis in adults with HIV. <i>Medicine (United States)</i> , 2022, 101, e30405.	1.0	6
380	Improving HIV medication adherence among forced migrants living with HIV: a qualitative study of refugees and asylum seekers in Malaysia. <i>Conflict and Health</i> , 2022, 16, .	2.7	2
381	Delays in third-line antiretroviral therapy and outcomes in North West province. <i>Southern African Journal of HIV Medicine</i> , 2022, 23, .	0.9	0
382	Single-cell sequencing resolves the landscape of immune cells and regulatory mechanisms in HIV-infected immune non-responders. <i>Cell Death and Disease</i> , 2022, 13, .	6.3	7
383	Trends in Use of Combination Antiretroviral Therapy and Treatment Response from 2000 to 2016 in the Canadian Observational Cohort (CANOC): A Longitudinal Cohort Study. <i>Canadian Journal of Hospital Pharmacy</i> , 2022, 75, 309-316.	0.1	0
384	Low-level viraemia: An emerging concern among people living with HIV in Uganda and across sub-Saharan Africa. <i>African Journal of Laboratory Medicine</i> , 2022, 11, .	0.6	1
385	Developing an app-based self-management program for people living with HIV: a randomized controlled pilot study during the COVID-19 pandemic. <i>Scientific Reports</i> , 2022, 12, .	3.3	2
386	Using joint models to study the association between CD4 count and the risk of death in TB/HIV data. <i>BMC Medical Research Methodology</i> , 2022, 22, .	3.1	2
387	A randomized prospective study to compare early versus delayed access to antiretroviral therapy over clinical and immunological sequel in HIV-positive adults. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 6959.	0.9	0
388	Uptake and effect of universal test-and-treat on twelve months retention and initial virologic suppression in routine HIV program in Kenya. <i>PLoS ONE</i> , 2022, 17, e0277675.	2.5	10
390	Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2023, 329, 63.	7.4	137
391	Predictors of delayed Anti-Retroviral Therapy initiation among adults referred for HIV treatment in Uganda: a cross-sectional study. <i>BMC Health Services Research</i> , 2023, 23, .	2.2	3
392	Optimizing the order of actions in a model of contact tracing. , 2023, 2, .		2
393	Recent Updates in the Management of HIV Infection. <i>Journal of Complementary and Alternative Medical Research</i> , 2023, 21, 16-23.	0.4	0

#	ARTICLE	IF	CITATIONS
394	Factors associated with rapid linkage to HIV medical care among persons newly diagnosed with HIV infection in the United States, 2019-2020. <i>Sexually Transmitted Diseases</i> , 0, Publish Ahead of Print, .	1.7	0
395	Factors associated to HIV prevalence among adolescent men who have sex with men in Salvador, Bahia State, Brazil: baseline data from the PrEP1519 cohort. <i>Cadernos De Saude Publica</i> , 2023, 39, .	1.0	7
396	Healthcare provider perceptions on the implementation of the universal test-and-treat policy in South Africa: a qualitative inquiry. <i>BMC Health Services Research</i> , 2023, 23, .	2.2	2
397	Human Immunodeficiency Virus in Pregnancy. <i>Obstetrics and Gynecology Clinics of North America</i> , 2023, , .	1.9	0
398	Strategies to increase HIV testing among men who have sex with men and transgender women: an integrative review. <i>BMC Infectious Diseases</i> , 2023, 23, .	2.9	1
400	Perceptions toward antiretroviral therapy and delayed ART initiation among people living with HIV in Changsha, China: mediating effects of treatment willingness. <i>Frontiers in Public Health</i> , 0, 11, .	2.7	0
401	Prevalence of Transmitted Drug Resistance among HIV-1 Patients in the Aegean Region: Results from the Western Part of Turkey. <i>Current HIV Research</i> , 2023, 21, 109-116.	0.5	1
403	Access to healthcare for people living with HIV: an analysis of judgments of the European Court of Human Rights from an ethical perspective. <i>Frontiers in Public Health</i> , 0, 11, .	2.7	0
404	Predictors of participant retention in a community-based HIV prevention cohort: perspectives from the HPTN 071 (PopART) study. <i>Trials</i> , 2023, 24, .	1.6	1
405	The Rapid interaction: a qualitative study of provider approaches to implementing Rapid ART. <i>Implementation Science Communications</i> , 2023, 4, .	2.2	0
406	Risk Factors and Associated Outcomes of Virulence Genes <i>eae</i> , <i>entB</i> , and <i>pipD</i> Carriage in <i>Escherichia coli</i> , <i>Klebsiella pneumoniae</i> , and <i>Salmonella</i> spp. From HIV-1 and HIV-Negative Gastroenteritis Patients in the Dschang Regional Hospital Annex. <i>Cureus</i> , 2023, , .	0.5	0
407	Perspectives of people living with HIV on barriers to timely ART initiation following referral for antiretroviral therapy: A qualitative study at an urban HIV clinic in Kampala, Uganda. <i>PLOS Global Public Health</i> , 2023, 3, e0001483.	1.6	0
408	Impact of latent <i>M. tuberculosis</i> infection treatment on time to CD4/CD8 recovery in acute, recent and chronic HIV infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2023, , .	2.1	0
409	Community- and individual-level correlates of HIV incidence in HPTN 071 (PopART). <i>Journal of the International AIDS Society</i> , 2023, 26, .	3.0	0
411	Control groups for HIV prevention efficacy trials: what does the future hold?. <i>Current Opinion in HIV and AIDS</i> , 2023, 18, 349-356.	3.8	2
412	Prevalence of HIV testing uptake among the never-married young men (15-24) in sub-Saharan Africa: An analysis of demographic and health survey data (2015-2020). <i>PLoS ONE</i> , 2023, 18, e0292182.	2.5	0
413	HIV test-and-treat policy improves clinical outcomes in Zambian adults from Southern Province: a multicenter retrospective cohort study. <i>Frontiers in Public Health</i> , 0, 11, .	2.7	0
415	Impact of the COVID-19 pandemic on routine HIV care and antiretroviral treatment outcomes in Kenya: A nationally representative analysis. <i>PLoS ONE</i> , 2023, 18, e0291479.	2.5	0

#	ARTICLE	IF	CITATIONS
416	HIV transmission and associated factors under the scale-up of HIV antiretroviral therapy: a population-based longitudinal molecular network study. <i>Virology Journal</i> , 2023, 20, .	3.4	0
417	Trends and factors associated with recent HIV testing among women in Haiti: a cross-sectional study using data from nationally representative surveys. <i>BMC Infectious Diseases</i> , 2024, 24, .	2.9	1
418	New Insights into HIV Life Cycle, Th1/Th2 Shift during HIV Infection and Preferential Virus Infection of Th2 Cells: Implications of Early HIV Treatment Initiation and Care. <i>Life</i> , 2024, 14, 104.	2.4	0
419	Time to tuberculosis development and its predictors among HIV-positive patients: A retrospective cohort study. <i>PLoS ONE</i> , 2024, 19, e0298021.	2.5	0
420	Utilizing local likelihood in regression discontinuity design: Investigating the impact of antiretroviral therapy eligibility on retention in clinical HIV care in South Africa. <i>Statistics in Medicine</i> , 2024, 43, 1640-1659.	1.6	0
422	HIV Services Uptake Among People Living with HIV in Jiangsu Province, China: A Cross-Sectional Study. <i>AIDS and Behavior</i> , 0, , .	2.7	0
423	Supporting good outcomes for early childhood home-visiting programmes: Guidelines for practice. <i>South African Journal of Childhood Education</i> , 2024, 14, .	0.3	0